Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTT-PET and ctDNA to Predict PARP Inhibitor Response in mPC
NCT07723651Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- May 2032
- Countries
- 1
01
Overview
A Phase 2 trial of [18F]FluorThanatrace in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Washington University School of Medicine. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07723651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723651.